Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film. We regard The Swedish Financial Supervisory Authority´s decision to investigate Klaria Pharma as a non-case-altering event. We believe Klaria potentially finding and signing a licensing agreement with a commercialisation partner for its sumatriptan alginate film in 2023 is essential for a positive share development. We make adjustments to our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/